Text size :

Rhinosinusitis with nasal polyps, De Corso (UniPg): “Mepolizumab improves disease control and quality of life”

ADNKRONOS

November 16, 2026

Rome, Nov 16. (Adnkronos Health) – “Meporeal is a phase 4 real-life study, published in ‘The Lancet Respiratory Medicine’, which enrolled more than 600 patients in 25 Italian centers and demonstrates the efficacy of mepolizumab in normal clinical practice for the treatment of patients with severe uncontrolled chronic rhinosinusitis with nasal polyps.” So Eugenio De Corso, professor of Otorhinolaryngology at the University of Perugia, commented on the results of the Meporeal study, published last August, which evaluated the efficacy of mepolizumab in severe chronic rhinosinusitis with nasal polyps.

“Chronic rhinosinusitis with nasal polyps is a chronic, debilitating, and progressive disease. 30% of patients suffer from severe and uncontrolled forms, and with biological drugs, we have managed to bring them back to a normal life,” emphasizes De Corso. “In the Meporeal study – the specialist continues – mepolizumab demonstrated efficacy in improving nasal symptoms and quality of life, achieving sustained control and, in a subgroup of patients, remission at 12 months. We are talking about a multimodal response: there is an improvement in quality of life, nasal symptoms, and comorbid asthma, achievement of sustained control over time, and a significant reduction in the use of systemic corticosteroids.”

“The challenges for the future concern the long-term management of patients. There are many novelties in research and biotechnological innovation in terms of new molecules. The most interesting ones are those that can lead to sustained control of inflammation and thus clinical control over time, also reducing the number of administrations per year and significantly extending the drug administration interval,” concludes the expert.

Jiji Press

Related

Page TOP